Currently out of the existing stock ratings of Graig Suvannavejh, 311 are a BUY (76.6%), 89 are a HOLD (21.92%), 6 are a SELL (1.48%).

Graig Suvannavejh

Work Performance Price Targets & Ratings Chart

Analyst Graig Suvannavejh, currently employed at MIZUHO, carries an average stock price target met ratio of 56.08% that have a potential upside of 35.05% achieved within 180 days.

Graig Suvannavejh’s has documented 804 price targets and ratings displayed on 58 stocks. The coverage is on Healthcare, Communication Services, Basic Materials, Technology, Consumer Defensive sectors.

Most recent stock forecast was given on VSTM, Verastem at 16-Oct-2026.

Wall Street Analyst Graig Suvannavejh

Analyst best performing recommendations are on BCYC (BICYCLE THERAPEUTICS LTD).
The best stock recommendation documented was for AMLX (AMYLYX PHARMACEUTICALS) at 8/17/2026. The price target of $30 was fulfilled within 1 day with a profit of $8.57 (39.99%) receiving and performance score of 399.91.

Average potential price target upside

of $75.17 (40.45%) on KRTX (KARUNA THERAPEUTICS).
of $70.92 (66.44%) on KOD (KODIAK SCIENCES).
of $48.05 (70.46%) on DBVT (DBV TECHNOLOGIES).

ALEC Alector ARQT Arcutis Biotherapeutics BTAI BioXcel Therapeutics CERE Cerevel Therapeutics Holdings CYTK Cytokinetics FLXN Flexion Therapeutics HALO Halozyme Therapeutics HRMY Harmony Biosciences Holdings INSM Insmed ITCI Intracellular Th JAZZ Jazz Pharmaceuticals PLC KOD Kodiak Sciences ORTX Orchard Therapeutics PLC TGTX TG Therapeutics ATHA Athira Pharma GMTX Gemini Therapeutics MOR MorphoSys AG ADR RYTM Rhythm Pharmaceuticals XEC Cimarex Energy Co AXSM Axsome Therapeutics RAIN Rain Therapeutics ADVM Adverum Biotechnologies AMLX Amylyx Pharmaceuticals HZNP Horizon Pharma PLC IMCR Immunocore Holdings Ltd IMTX Immatics NV MNTA Momenta Pharmaceuticals PTLA Portola Pharmaceuticals TCDA Tricida AUTL Autolus Therapeutics Ltd EYPT Eyepoint Pharmaceuticals KRTX Karuna Therapeutics TERN Terns Pharmaceuticals VIGL Vigil Neuroscience APLS Apellis Pharmaceuticals CRVS Corvus Pharmaceuticals VALN Valneva SE ADR ADAP Adaptimmune Therapeutics Plc BCYC Bicycle Therapeutics Ltd CRBP Corbus Pharmaceuticals IMRX Immuneering Corp IDYA Ideaya Biosciences VSTM Verastem ZEAL Zealand Pharma A/S ADR BLTE Belite Bio ADR ADV Advantage Solutions AMAM Ambrx Biopharma CE Celanese DSGN Design Therapeutics ERAS Erasca GLPG Galapagos NV ADR IT Gartner KRYS Krystal Biotech NMRA Neumora Therapeutics MO Altria Group GMAB Genmab AS TARS Tarsus Pharmaceuticals DBVT DBV Technologies

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Sean Laaman (MORGAN STANLEY)

Sell Since 07-Mar-2025

$0.79 (35.75%)

28 days ago
(06-Oct-2026)

2/3 (66.67%)

$1.19 (65.75%)

Please subscribe to see extended stock data

Thomas Shrader (BTIG)

Hold Since 10-Mar-2026

$3.79 (171.49%)

7 months 24 days ago
(10-Mar-2026)

1/6 (16.67%)

$3.62 (152.10%)

Please subscribe to see extended stock data

Andrew Fein (HC WAINWRIGHT)

Buy Since 24-Jun-2020

$3.14 (168.82%)

$10

1 years 11 days ago
(23-Oct-2025)

0/9 (0%)

$3.53 (240.14%)

Please subscribe to see extended stock data

Myles Minter (WILLIAM BLAIR)

Hold Since 22-Oct-2025

1 years 12 days ago
(22-Oct-2025)

0/1 (0%)

$9.01 (37.56%)

Please subscribe to see extended stock data

Pete Stavropoulos (CANTOR FITZGERALD)

Hold Since 22-Oct-2025

1 years 12 days ago
(22-Oct-2025)

0/1 (0%)

$6.12 (88.95%)

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Graig Suvannavejh most bullish on?

Potential upside of $171.57 has been obtained for AXSM (AXSOME THERAPEUTICS)

Which stock is Graig Suvannavejh most reserved on?

Potential downside of $1.14 has been obtained for AMLX (AMYLYX PHARMACEUTICALS)

What Year was the first public recommendation made by Graig Suvannavejh?

On 2018